SELLAS Announces Promising Data from Phase 2a Study of SLS009 in Relapsed/Refractory AML and Receives FDA Fast Track Designation
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a leading clinical biopharmaceutical company focused on developing innovative cancer therapies, has recently made significant advancements in the study and development of SLS009 for the treatment of relapsed/refractory acute myeloid leukemia (AML). The company has announced positive topline data from the Phase 2a study of SLS009 and received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for this potential breakthrough therapy.
The Phase 2a study of SLS009 involved evaluating its safety and efficacy in patients with relapsed/refractory AML. Enrolling a total of 45 patients in the 45 mg safety cohort, the study has revealed promising results. The median overall survival (OS) has not yet been reached, indicating the potential for improved survival rates. Furthermore, an incredible 89% of patients in the safety cohort remain alive, and a significant antileukemic effect has been observed in 87.5% of evaluable patients.
SELLAS’ highly selective CDK9 small molecule inhibitor, SLS009, has demonstrated its potent anti-proliferative effects in various hematologic malignancies. The underlying mechanisms of action behind these effects have been unveiled in a publication in the renowned scientific journal Oncotarget. This publication sheds light on SLS009’s ability to selectively target and inhibit CDK9, a protein involved in cell division and growth, leading to cancer cell death.
The positive results from the Phase 2a study and the understanding of SLS009’s mechanisms of action have prompted the FDA to grant Fast Track Designation for this potential therapy. This designation facilitates the development and expedites the review process of drugs that treat serious conditions and demonstrate the potential to fill an unmet medical need. SLS009’s Fast Track Designation signifies its promise in addressing the urgent need for effective treatments for relapsed/refractory AML patients.
SELLAS is not only making notable progress in the clinical development of SLS009 but also actively advancing its Phase 3 REGAL Study. The enrollment for this study, evaluating the use of GPS (a combination therapy including SLS009) in AML patients, has been successfully completed. The Steering Committee is now guiding interim analysis, which is expected to provide crucial insights into the therapy’s effectiveness. The Independent Data Monitoring Committee (IDMC) has been scheduled for late April, further indicating the dedication and comprehensive approach taken by SELLAS to ensure the success of this study.
The positive topline data from the Phase 2a study, the FDA Fast Track Designation, the published preclinical data revealing the mechanisms of action of SLS009, and the progress of the Phase 3 REGAL Study all underscore the potential of SLS009 as a groundbreaking therapy for relapsed/refractory AML patients. SELLAS is committed to advancing SLS009 through further clinical development and regulatory approval to provide much-needed hope and improved outcomes for patients with this devastating disease.
Comments